Danaher (NYSE:DHR – Get Free Report) and IceCure Medical (NASDAQ:ICCM – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, institutional ownership, dividends, valuation and risk.
Institutional & Insider Ownership
79.1% of Danaher shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 11.1% of Danaher shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Danaher has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Danaher | 0 | 3 | 19 | 0 | 2.86 |
| IceCure Medical | 1 | 1 | 1 | 0 | 2.00 |
Danaher currently has a consensus target price of $253.55, suggesting a potential upside of 33.83%. IceCure Medical has a consensus target price of $2.64, suggesting a potential upside of 319.32%. Given IceCure Medical’s higher probable upside, analysts plainly believe IceCure Medical is more favorable than Danaher.
Profitability
This table compares Danaher and IceCure Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Danaher | 14.71% | 10.81% | 6.90% |
| IceCure Medical | -445.61% | -221.04% | -118.89% |
Valuation and Earnings
This table compares Danaher and IceCure Medical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Danaher | $24.57 billion | 5.45 | $3.61 billion | $5.04 | 37.59 |
| IceCure Medical | $3.38 million | 13.59 | -$15.32 million | ($0.24) | -2.62 |
Danaher has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks.
Summary
Danaher beats IceCure Medical on 12 of the 14 factors compared between the two stocks.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
